Incidence of Diabetes Mellitus and Obesity and the Overlap of Comorbidities in HIV+ Hispanics Initiating Antiretroviral Therapy by Gomes, Angelina et al.
RESEARCH ARTICLE
Incidence of Diabetes Mellitus and Obesity
and the Overlap of Comorbidities in HIV+
Hispanics Initiating Antiretroviral Therapy
Angelina Gomes1¤a, Emily V. Reyes2¤b, L. Sergio Garduno3¤c, Rita Rojas2¤d, Geraldine Mir
Mesejo4, Eliza Del Rosario4, Lina Jose2, Carmen Javier2, Catherine Vaughan1¤e,
Yeycy Donastorg5, Scott Hammer1, Karen Brudney1, Barbara S. Taylor1,3*
1 Department of Medicine, Columbia University Medical Center, New York, New York, United States of
America, 2 Unidad de Tratamiento de ITS y VIH, Instituto Dermatológico y Cirugía de Piel “Dr. Humberto
Bogaert Diaz”, Santo Domingo, Dominican Republic, 3 University of Texas Health Science Center San
Antonio, San Antonio, Texas, United States of America, 4 Departamento de Medicina, Profamilia, Santo
Domingo, Dominican Republic, 5 Unidad de Vacunas, Instituto Dermatológico y Cirugía de Piel “Dr.
Humberto Bogaert Diaz”, Santo Domingo, Dominican Republic
¤a Current address: Department of Medicine, New York University, New York, New York, United States of
America
¤b Current address: Departamento de Infectología, Hospital Salvador B. Gautier, Santo Domingo,
Dominican Republic
¤c Current address: College of Criminology & Criminal Justice, Florida State University, Tallahassee,
Florida, United States of America
¤d Current address: Departamento de Infectología, Hospital General de la Plaza de la Salud, Santo
Domingo, Dominican Republic




Cardiovascular disease (CVD) is a leading health threat for HIV+ patients on antiretroviral
therapy (ART); cardiometabolic comorbidities are key predictors of risk. Data are limited on
incidence of metabolic comorbidities in HIV+ individuals initiating ART in low and middle
income countries (LMICs), particularly for Hispanics. We examined incidence of diabetes
and obesity in a prospective cohort of those initiating ART in the Dominican Republic.
Methods
Participants18 years, initiating ART <90 days prior to study enrollment, were examined
for incidence of impaired fasting glucose (IFG), diabetes mellitus (DM), overweight, and
obesity. Fasting plasma glucose (FPG) 100-125mg/dl defined IFG; FPG126 mg/dl, diag-
nosis per medical record, or use of hypoglycemic medication defined DM. Overweight and
obesity were BMI 25–30 and30kg/m2, respectively. Dyslipidemia was total cholesterol
240mg/dl or use of lipid-lowering medication. Framingham risk equation was used to
determine ten-year CVD risk at the end of observation.
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Results
Of 153 initiating ART, 8 (6%) had DM and 23 (16%) had IFG at baseline, 6 developed DM
(28/1000 person-years follow up [PYFU]) and 46 developed IFG (329/1000 PYFU). At base-
line, 24 (18%) were obese and 36 (27%) were overweight, 15 became obese (69/1000
PYFU) and 22 became overweight (163/1000 PYFU). Median observation periods for the
diabetes and obesity analyses were 23.5 months and 24.3 months, respectively. Increased
CVD risk (10% 10-year Framingham risk score) was present for 13% of the cohort; 79% of
the cohort had1 cardiometabolic comorbidity, 48% had2, and 13% had all three.
Conclusions
In this Hispanic cohort in an LMIC, incidences of IFG/DM and overweight/obesity were simi-
lar to or higher than that found in high income countries, and cardiometabolic disorders
affected three-quarters of those initiating ART. Care models incorporating cardiovascular
risk reduction into HIV treatment programs are needed to prevent CVD-associated mortality
in this vulnerable population.
Introduction
The advent of antiretroviral therapy (ART) has greatly increased life expectancy for people liv-
ing with HIV (HIV+),[1] but cardiovascular disease (CVD) is now a leading health threat in
patients receiving ART.[2–5] HIV infection confers increased risk for CVD,[3, 6] and is linked
to ART-induced dyslipidemia,[7–9] the chronic inflammation induced by HIV infection,[3,
10, 11] and conventional risk factors for CVD, like increasing age, minority race, smoking, dys-
lipidemia, and obesity.[4, 12–15] As HIV+ individuals’ lifespans approach that of the general
population, the management of modifiable cardiovascular risk factors becomes increasingly
important.
Although research in low and middle income countries (LMICs) has demonstrated increas-
ing prevalence of diabetes and obesity in HIV+ individuals initiating antiretroviral therapy,
[16–20] little is known regarding the incidence of obesity in HIV+ individuals initiating antire-
troviral therapy in Latin America, a region heavily impacted by the global obesity epidemic.
The incidence of diabetes has been measured in only two studies in LMICs, and few data exist
on the incidence of diabetes in HIV+ individuals living in Latin America. Given the known
increased risk of metabolic disorders such as diabetes and obesity in HIV-uninfected Hispanics
in the United States (U.S.),[21–23] Hispanics in LMICs may be at high risk for developing met-
abolic complications after ART initiation.
The Dominican Republic (DR) is an ideal setting in which to examine the incidence of cardi-
ometabolic complications after ART initiation. It is a resource-constrained country in the Carib-
bean with a high burden of obesity (26.6%), diabetes mellitus (9.9%), and dyslipidemia (12.3%),
[24] and CVD is the leading cause of death (35%).[25] The Dominican national HIV treatment
program currently provides ART to 48% of people in need of treatment,[26] ensuring a near
normal lifespan for these individuals. However, this success could be jeopardized by HIV’s long-
term cardiometabolic complications in a population already highly impacted by CVD.
We hypothesized that the known baseline increased risk of obesity and diabetes for HIV
uninfected Hispanics in the U.S. could lead to increased risk of these conditions in HIV+ His-
panics receiving care in LMICs. We determine the incidence and overlap of key CVD risk
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factors: diabetes mellitus (DM), impaired fasting glucose (IFG), obesity, and overweight BMI
in a longitudinal, prospective cohort of HIV+ patients initiating ART. We also examined the
overall CVD risk and prevalence of cardiometabolic comorbidities. Our findings may have
implications for ART expansion in LMICs, as cardiometabolic comorbidities would reduce the
improvements in life expectancy offered by effective HIV treatment.
Methods
Study Patients
Patients included in this analysis participated in the Dominican HIV Cohort, a prospective,
observational cohort study of HIV treatment outcomes in the DR from September 1, 2007
through May 31, 2013. Continuous enrollment took place at two adult HIV treatment centers
in Santo Domingo, Dominican Republic, participating in the Dominican national ART pro-
gram. Physicians and patient educators in the clinic offered enrollment to individuals initiating
or already receiving ART. Of those offered enrollment, approximately 75% accepted. The pri-
mary reasons for refusal were work conflicts or living at a distance from the clinic. The cohort
population was representative of the general clinic population.
Patients were included in this study if they initiated combination ART within 90 days prior
to or any time after the first study visit. Patients were excluded if they had previously taken
combination ART. Study patients were included in the analysis of DM and IFG if they had a
baseline fasting plasma glucose (FPG) measurement180 days prior to ART start date, and a
second measurement2 weeks after ART initiation. Non-pregnant study patients were
included in the analysis of obesity and overweight BMI if measurements of height and weight
were taken180 days prior to or30 days after ART start, and again180 days after ART ini-
tiation. The distribution of cohort patients in the two analyses is represented in Fig 1. Partici-
pants were followed throughout the observation period with visits every 3 months in the first
year of participation and every 6 months thereafter.
Outcomes
Our primary outcomes of interest for this study were incidence of: (1) DM or IFG, and (2) obe-
sity or overweight BMI. DM was defined as at least one FPG126 mg/dl, documented use of
hypoglycemic medication, or DM diagnosis per the medical record, as in other studies in
LMICs and other settings where confirmatory testing is not always available.[27–29] IFG was
defined as at least one FPG 100 mg/dl and no FPG126 mg/dl. DM observation endpoint
was the first date at which patients met criteria for DM, or the date of last FPG if patients did
not meet criteria for DM. Eight individuals who were determined to have DM at baseline were
excluded from further DM-related analyses described below.
Obesity was defined as BMI30 kg/m2 and overweight as BMI25 kg/m2. Observation
endpoint dates were the first date when patients met criteria for obesity, or the date of the last
BMI if patients never met criteria for obesity. Twenty-four patients who were obese at baseline
were excluded from the incidence analyses.
Covariates
Demographics. Demographic variables included gender, age at the beginning of the obser-
vation period, and HIV transmission categories. Self-reported transmission categories were
categorized as heterosexual sex, men who have sex with men (MSM), and other, including
unknown or missing. No patients reported maternal to child transmission or injection drug
use as HIV transmission risk.
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HIV disease parameters. We calculated the years since HIV diagnosis at the beginning of
the observation period, and the duration of HIV diagnosis from diagnosis to the endpoints of
our primary outcomes. Immunologic status was categorized, based on CD4 count taken180
days prior to and closest to ART start date (hereafter baseline CD4 count), as<200 or200
cells per microliter. Baseline viral load status, based on HIV-1 RNA assay taken180 days
prior to and closest to ART start date, was unavailable for most of the cohort because pre-ART
testing is not offered within the Dominican national program, but when available, was catego-
rized as<1000 or1000. Endpoint immunologic and virologic status were categorized, based
on CD4 counts and HIV-1 plasma RNA assays measured within ±180 days from each
Fig 1. Distribution of cohort patients between impaired fasting glucose/diabetes and overweight/
obesity analyses. ART: antiretroviral therapy; BMI: body mass index; FPG: fasting plasma glucose; LFTU:
lost to follow up. *Baseline for DM analysis defined as180 days prior to ART start date. **Baseline for
obesity analysis defined as BMI measured180 days prior to ART start date or up to 30 days after ART start.
†Post ART FPGmeasured2 weeks after ART initiation. ‡Post ART BMI measured180 days after ART
initiation.
doi:10.1371/journal.pone.0160797.g001
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endpoint, as<200 or200 cells per microliter and<400 or400 copies per milliliter, respec-
tively. Exposure to ART, defined as the use of2 NRTIs (stavudine, lamivudine, emtricitabine,
zidovudine, tenofovir, or abacavir) with1 PI (lopinavir/ritonavir) or 1 NNRTI (nevirapine or
efavirenz), was calculated in months from the ART initiation date to each outcome endpoint.
These were the only combinations of ART available, as first and second line treatment, through
the Dominican national HIV treatment program. Months on PIs and NNRTIs were calculated
from treatment initiation date of the drug class to each outcome endpoint.
Other clinical variables. Dyslipidemia was defined as1 measurement of total cholesterol
240 mg/dl, per the National Cholesterol Education Program (NCEP ATP III) guidelines,[30]
or documented use of lipid lowering medication in the presence of normal serum cholesterol
levels. As statins are relatively inaccessible due to cost in the DR, we included statins, fibrates,
cholesterol absorption inhibitors, niacin, and bile acid resins as lipid-lowering therapy. Hyper-
tension was defined as2 blood pressure measurements with systolic blood pressure140 or
diastolic blood pressure90, as per the Joint National Committee seventh report guidelines, or
as the use of anti-hypertensive medications as documented in the medical record.[31]
Patients were asked about use of tobacco, alcohol, and drug use every 6 months. Tobacco
users were classified as current users or not current users, as per the Framingham CVD equation.
Substance users were categorized as current users or non-current users throughout the observa-
tion period. Alcohol use was categorized as average number of drinks consumed per month over
the observation period. Depression was defined as any positive response during the observation
period to the Patient Health Questionnaire-2 (PHQ-2),[32] administered at each cohort visit.
Ten-year CVD risk scores were calculated at the end of observation with the Framingham
CVD equation for those patients aged 30–74.[33, 34] Patients were included in calculations if
their last HDL measurement was taken30 days after ART initiation, they had a blood pres-
sure measurement taken within 1 year of their last HDL measurement, and had no reported
history of CVD. Overall prevalence of cardiometabolic multi-morbidity was assessed by deter-
mining the overlapping prevalence of 1) IFG/DM, 2) overweight/obesity, and 3) dyslipidemia.
Statistical Analysis
Bivariate analysis assessed associations between outcomes and the covariates above. Pearson
Chi-square tests or Fisher’s Exact test tested associations between categorical variables. All con-
tinuous variables were non-normally distributed, so Mann-Whitney U tests determined differ-
ences in medians of continuous covariates by outcome. Survival analysis with Kaplan-Meier
curves described incidence of DM, IFG, obesity, and overweight during the observation period.
All analyses conducted 2-sided, with a significance cutoff of p<0.05 in IBM SPSS Statistics ver-
sion 22 (Armonk, New York) and R version 3.1.0 (R Foundation for Statistical Computing,
Vienna, Austria).
Ethical considerations and funding source
Patients provided written informed consent prior to participating. The study protocol was
approved by the Dominican National Committee on Bioethics (CONABIOS), the ethics com-
mittees of the Instituto Dermatológico y Cirugía de Piel “Dr. Huberto Bogaert Diaz” and Profa-
milia, and the Institutional Review Boards at Columbia University Medical Center and
University of Texas Health Science Center at San Antonio.
Results
Of patients initiating ART within the cohort in 2007–2013, 140 met inclusion criteria for the
fasting glucose analysis and 133 met inclusion criteria for the BMI analysis (Fig 1). The median
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observation period was 34.8 months. The cohort was 57% female, with a median age of 39 (33–
45), a median duration of HIV diagnosis of 3 years (IQR: 0–7), and heterosexual transmission
was the dominant HIV risk factor (Table 1).
Incidence of impaired fasting glucose and diabetes mellitus
Of 140 patients in the diabetes analysis, 8 (6%) had DM and 23 (16%) had IFG at baseline,
defined henceforth as180 days prior to starting ART. After ART initiation, 6 of 113 (5%)
patients with either normoglycemic or IFG measurements at baseline developed DM, resulting
in an incidence of 28 per 1000 PYFU (Fig 2). Forty-six of 91 (51%) patients who were normo-
glycemic at baseline developed IFG, resulting in an incidence of 329 per 1000 PYFU. Patients
with IFG had received ART for a median duration of 24 months (IQR: 13–39) when they met
Table 1. Baseline characteristics of participants.
DEMOGRAPHIC CHARACTERISTICS N (%)*
Total No. Patients 153
Women1 87 (57%)
Median age at baseline2 in years (IQR) 39 (33–45)
HIV transmission risk category3
Heterosexual 138 (90%)
MSM 7 (5%)
Other (work exposure, blood transfusion, unknown) 9 (6%)
HIV DISEASE PARAMETERS
Median duration of HIV in years at baseline2 (IQR) 3 (0–7)
Baseline2 CD4 <200 cells/μL (of 145 available) 66 (46%)
Median baseline2 CD4 (cells/μL) (IQR) 211 (135–265)
Baseline2 VL <1000 copies/mL (of 58 available) 4 (7%)
Median baseline2 VL (copies/mL) (IQR) 74,241 (18,784–178,5804)
Initiated ART with PI-based regimen 5 (3%)
Initiated ART with NNRTI-based regimen 148 (97%)
CARDIOVASCULAR RISK FACTORS
Median baseline BMI4 (kg/m2) (IQR) 24.5 (22–28)
Hypertension5 30(20%)
Lipid lowering medication use 22 (14%)
Current smoker 21 (14%)
OTHER RELEVANT CLINICAL CHARACTERISTICS
Depressive symptoms during observation period 126 (82%)
Current drug use (heroin, crack/cocaine, marijuana, or ecstasy) 9 (6%)




* Percent unless otherwise specified
1 No patients identified as transgender in this cohort
2Baseline measures taken180 days prior to ART initiation
3 No patients reported transmission risk factors of intravenous drug use or vertical transmission
4Body mass index, baseline measures taken180 days prior to ART initiation or 30 days after ART
initiation
5 Hypertension was defined as systolic blood pressure140 or diastolic blood pressure90
doi:10.1371/journal.pone.0160797.t001
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endpoint criteria. Fifteen (13%) patients received a PI containing regimen over the course of
the observation period, but PI use was not statistically significantly associated with develop-
ment of IFG or DM (p = 0.424). Those with the combined endpoint of incident IFG/DM were
more likely to have dyslipidemia (OR, 8.23, 95% CI: 2.23 to 30.4). No other covariates, includ-
ing baseline or endpoint CD4 count and HIV RNA levels, were statistically significant predic-
tors of incident DM or IFG. The median observation period for patients included in the DM
analysis was 23.5 months (IQR: 16.1–37.9). At the end of observation, a total of 14 (10%) and
69 (49%) patients met criteria for DM and IFG, respectively.
Incidence of overweight and obesity
Of 133 patients in the obesity analysis, 24 (18%) were obese and 36 (27%) were overweight at
baseline. At least 6 months after initiating ART, 15 (15%) patients became obese from normal
Fig 2. Kaplan-Meier curves representing risk of developing impaired fasting glucose /diabetes. Pink
line represents the risk of developing diabetes (DM) and blue line represents risk of the combined endpoint of
impaired fasting glucose (IFG)/DM, from normoglycemic baseline as a function of the number of months of
ART. DM defined as1 fasting plasma glucose (FPG)126, documented use of hypoglycemic medication,
or DM diagnosis per the medical record. IFG defined as1 FPG 100 mg/dl and no FPG126 mg/dl.
Vertical tick-marks indicate patients whose survival times have been right-censored. Dashed lines represent
95% confidence intervals.
doi:10.1371/journal.pone.0160797.g002
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or overweight BMIs, resulting in an incidence of 69 per 1000 PYFU (Fig 3). Twenty-two (33%)
patients became overweight from normal baseline BMI, resulting in an incidence of 163 per
1000 PYFU. Incident obesity after ART initiation was associated with: age over 50 years (OR
9.88; 95%CI: 2.27, 42.9), and dyslipidemia (OR, 2.72; 95%CI: 1.20, 6.17). No statistically signifi-
cant association with duration of PI use, baseline or endpoint CD4 count, or HIV RNA levels
were observed. The median observation period for patients included in the obesity analysis was
24.3 months (IQR: 15.4–39.5). Patients with incident obesity had received ART for a median
duration of 8 months (IQR: 7–12) when they developed BMI30 kg/m2. Few patients lost
weight after becoming obese or overweight; eight patients went from obese to overweight, no
obese patients reached a normal BMI (<25 kg/m2), and ten patients went from overweight to a
normal BMI by the end of observation. However, whether this weight loss was intentional is
difficult to determine. Considering changes in weight, at the end of observation, 24% of the
cohort was obese and 42% was overweight.
Fig 3. Kaplan-Meier curves representing risk of developing overweight/obese BMI. Blue line represents
risk of developing obesity and orange line represents risk of the combined endpoint of overweight/obese BMI
from normal BMI at baseline as a function of the number of months of ART. Obesity was defined as BMI30
kg/m2 and overweight as BMI25 kg/m2. Vertical tick-marks indicate patients whose survival times have
been right-censored. Dashed lines represent 95% confidence intervals.
doi:10.1371/journal.pone.0160797.g003
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Burden of Cardiometabolic Risk
Framingham ten-year year risk scores were calculated for the 82 patients>30 years of age,
with a median age of 42.4 (IQR: 38.2–50.6) at the time of score calculation. Two (2%) patients
were classified as high risk (>20%), and nine (11%) were at moderate risk (10–20%). Two indi-
viduals suffered cardiovascular events during the observation period and were excluded from
risk calculations. Thirty (20%) patients met criteria for hypertension, twenty (67%) of whom
were receiving anti-hypertensive medication. Of those receiving treatment, seven (35%)
patients had uncontrolled blood pressure,>140/90 (or 130/80 for diabetics) at their last
measurement.
Thirty-five (24%) of 143 patients who had lipid panels measured during observation had
dyslipidemia based on serum lipid measurements or use of lipid-lowering medications. Analy-
sis of the overall prevalence of cardiometabolic multi-morbidity (IFG/DM, overweight/obesity,
or dyslipidemia) revealed 79% of the cohort had at least one cardiometabolic comorbidity, 48%
had two or more, and 14% had all three (Fig 4). Seventy-five percent of patients had at least
one of these comorbidities within one year after ART initiation.
Discussion
In this first study to determine incidence and predictors of new onset impaired fasting glucose,
diabetes, overweight, and obesity following ART initiation in a longitudinal observational
cohort in Latin America, we find a high incidence of these outcomes, most of which occurred
within the 12 months following ART start. There was also a 13% prevalence of elevated CVD
risk per the Framingham risk score, and a striking degree of overlap between cardiometabolic
comorbidities, with the vast majority (79%) having at least one risk factor and almost half
(48%) having two or more metabolic risks. These data have direct implications for HIV treat-
ment programs in the region, and indicate that they should plan for an increase in metabolic
and cardiac risk in many of those initiating ART.
The incidence of insulin resistance that we found in our cohort is concerning, as impaired
fasting glucose was observed in almost half of our cohort in a span of two years, despite the fact
that very few patients (13%) were receiving protease inhibitors, which are traditionally associ-
ated with this phenomenon,[12, 13, 29, 35] but not recommended for patients initiating ART
in the DR. At the time of writing, a number of investigators have noted the rising prevalence of
diabetes in LMIC,[16, 17] but only two studies have examined the incidence of diabetes in
LMICs outside of Latin America: one in the Democratic Republic of Congo reported DM inci-
dence of 9.8/1000 PYFU, and one in Thailand reporting DM incidence of 5/1000 PYFU.[36,
37] Other data from Latin America imply that the prevalence of diabetes and cardiovascular
risk in people living with HIV is increasing; one cross-sectional study suggests high prevalence
of DM in an aging population of HIV+ individuals, and an additional study in Brazil shows
that the rate of increase in deaths attributable to CVD and DM is higher among HIV+ individu-
als compared to those without HIV.[16, 17]
The reported incidence of DM among HIV+ individuals in high income countries ranges
from 4.42 to 47 cases per 1000 PYFU, placing the incidence seen in our cohort (28/1000
PYFU) at the high end of that seen in high income settings.[7, 13, 29, 35] Although prior stud-
ies have demonstrated an association between PI use and increased incidence of DM and dysli-
pidemia, [12, 13, 29, 35, 38, 39] we did not observe this association, though sample size of those
exposed to PIs at any point was limited. It is possible that future increased access to integrase
and strand transfer inhibitors in LMICs could further reduce the risk of IFG and DM.
Research has demonstrated rising prevalence of obesity in HIV+ cohorts in high income
countries,[40] however, to our knowledge, no data on the incidence of obesity in observational
Incidence of Diabetes and Obesity in HIV+ Hispanics in the Caribbean
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HIV+ cohorts in Latin America exist. A randomized control trial of early ART and isoniazid
treatment in Western Africa (ANRS 12136 Temprano Trial) demonstrated that obesity preva-
lence increased from 7.2% prior to ART start to 9.2%, and overweight prevalence rose from
20.4% to 24.8% after 24 months of ART.[19] Our data speak to the growing burden of obesity
Fig 4. Burden of cardiometabolic comorbidities. Venn diagram representing the burden of overlapping cardiometabolic morbidity within the
cohort of patients initiating antiretroviral therapy, depicting the combined endpoints of impaired fasting glucose/diabetes mellitus (pink), overweight/
obesity (yellow), and dyslipidemia (blue), and the percentage of overlapping prevalence of these disorders. Definitions of these outcomes can be
found in methods section.
doi:10.1371/journal.pone.0160797.g004
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in cohorts initiating ART in Latin America, given the 45% prevalence of overweight/obesity
seen in this cohort prior to ART start, and the 65% at the end of a median 2.9 years of observa-
tion. Recently published data from a sub-sample of the AIDS Clinical Trials Group PEARLS
trial, which included data from 8 LMICs, 3 of which were in Latin America, show a rise in prev-
alence of overweight/obesity from 27% prior to ART initiation to 37% at 48 weeks after ART
initiation.[20] Additionally, the weight gain seen in our cohort is unlikely solely attributable to
food provision for HIV+ patients, as food provision is not a standard part of the Dominican
national treatment program, nor was it available to cohort participants. The 24% obesity preva-
lence seen at the end of our study is comparable to cross sectional studies the U.S. and Brazil
(17 to 32%).[41–49] The similar rates of obesity between this LMIC and more developed coun-
tries is particularly problematic given the limited access to primary care in the Dominican
Republic, posing a greater challenge for controlling CVD risk in these patients. The association
seen between BMI and dyslipidemia in our cohort implies that there are direct metabolic con-
sequences for the weight gain observed in this cohort.
Using the Framingham CVD risk calculator to assess ten-year cardiovascular risk in the
cohort, we found a 13% prevalence of elevated CVD risk. This is higher than other studies of
HIV+ individuals in LMICs: 10.7% in Nigeria, 9.9% in Thailand, and 3.6% in Uganda, but
comparable to the 11–18% prevalence found in a study of HIV negative individuals in Latin
America.[23, 50–52] This is concerning as our cohort is slightly younger than the Latin Ameri-
can cohort (median ages 42.4 vs. 44.6), and the Framingham risk score is known to underesti-
mate CVD risk in HIV+ individuals.[3, 53] Of the thirty participants who met criteria for
hypertension in this sample, seventeen (57%) were uncontrolled, either meeting criteria for
hypertension but not on treatment, or on treatment with last blood pressure>140/90 (130/80
for diabetics). Improving control of hypertension in this population could be an effective way
to mitigate this elevated CVD risk. The high degree of overlap between IFG/DM, overweight/
obesity, and dyslipidemia, with 48% of the cohort having two or more of these conditions,
speaks to the burden of CVD risk within the cohort and parallels findings of a prior investiga-
tion which found an association between dyslipidemia and new-onset DM.[7]
Certain limitations should be noted. The ADA suggests using two FPG to diagnose DM, but
a confirmatory measurement was not routinely available in this LMIC. However, prior studies
have reported DM incidence using one FPG measurement.[27–29] Many lipid panels were not
fractionated, which narrowed our definition for dyslipidemia and reduced the number of
patients for whom we could calculate CVD risk scores. The prevalence of metabolic syndrome
could not be assessed in this cohort because the definition would require waist circumference
measurements or an assessment of visceral adipose tissue, fractionated lipid panels, and inflam-
matory biomarker data for all patients, which were not available. We did not collect family his-
tory of DM, or other CVD or risk factors. Information bias may affect our sample; we did not
include those patients missing FPG or BMI measurements after initiation of ART, some of
whom were lost to follow up and may have been more seriously ill. The small sample size did
not provide enough power to undertake an analysis of the differential impact of ART drug type
on metabolic parameters. Lastly, the follow up in this cohort is relatively short, with a median
observation time of 2.9 years after ART initiation. Despite this limitation, we saw increases in
our outcomes of interest that were clinically important.
Our findings of high incidence of diabetes and obesity after ART initiation have significant
clinical implications for the management of care for HIV+ patients in Latin America. It is con-
cerning that, after a median 24 months on ART, over half the cohort met criteria for IFG or
DM, and half were overweight or obese. The burden of metabolic comorbidity is worrisome as
a majority (87%) of these patients was receiving NNRTI-based regimens, which are less associ-
ated with insulin resistance than PI-based regimens. Many programs providing HIV care in
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LMICs, including those in the DR, are “silo-ed” into clinics focused on HIV treatment, and not
integrated with primary care. Our findings demonstrate missed opportunities for lipid control,
hypertension control, and lifestyle interventions that could reduce risk for obesity and DM.
Given the rapid development of IFG/ DM and overweight/obesity after ART initiation, and the
high prevalence of overlapping cardiometabolic risks in this cohort, we advocate for the inte-
gration of assessment and treatment of cardiovascular risk into HIV care.
This increased risk for CVD is particularly important in Latin American settings, as cardiovas-
cular risk is highly prevalent in the general population and is a significant cause of mortality in
the region.[21–23] If these risks are not addressed, gains in life expectancy from successful ART
could be erased by morbidity and mortality from cardiovascular disease. Data regarding diabetes
and obesity incidence in larger Latin American cohorts would be useful to define this risk. Inno-
vative care models that incorporate cardiovascular risk reduction and non-communicable disease
care into HIV treatment programs in LMICs are needed to prevent cardiovascular disease.
Supporting Information
S1 Data Set. Data Underlying Findings Reported in Manuscript. Variable definitions are
included in second sheet.
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